Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00862654Phase 3Completed
Phase 3, randomised trial of clobetasol in seborrheic dermatitis (SD) (4 arms), sponsored by Galderma. Primary endpoint: Total Severity Score at 4 weeks. Started Mar 2009; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00862654.